1996
Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201: Results of a phase III multicenter trial
Hendel R, Verani M, Miller D, Wackers F, McMahon M, Cerqueira M, Botvinick E, Kvols L, Gerson M. Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201: Results of a phase III multicenter trial. Journal Of Nuclear Cardiology 1996, 3: 291-300. PMID: 8799247, DOI: 10.1016/s1071-3581(96)90088-4.Peer-Reviewed Original ResearchConceptsMyocardial perfusion agentPerfusion agentMulticenter trialNormalcy ratePhase III multicenter trialCoronary artery diseaseTomographic myocardial perfusionMyocardial perfusion imagingPanel of readersNew myocardial perfusion agentNew perfusion tracerPeak exerciseArtery diseaseThallium scintigraphyPerfusion scintigraphyMyocardial scintigraphyExercise workloadStudy groupLaboratory alterationsMyocardial perfusionThallium-201Perfusion imagingDiagnostic utilityScintigraphyPerfusion studies
1993
Assessing myocardial reperfusion with technetium-99m-labeled myocardial perfusion agents: basic concepts and clinical applications.
Sinusas AJ, Wackers FJ. Assessing myocardial reperfusion with technetium-99m-labeled myocardial perfusion agents: basic concepts and clinical applications. American Journal Of Cardiac Imaging 1993, 7: 24-38. PMID: 10148381.Peer-Reviewed Original ResearchConceptsVessel patencyPerfusion agentManagement of patientsAcute myocardial infarctionAssessment of reperfusionClinical applicationAcute coronary reperfusionMyocardial perfusion agentThrombolytic eraCoronary reperfusionMyocardial reperfusionPotential clinical applicationsMyocardial salvageMyocardial infarctionNoninvasive evaluationReperfusionPatencyResidual viabilityThrombolysisPatientsUnique biological propertiesBiological propertiesReocclusionInfarctionPerfusion